Legal & General Group PLC Nuvalent, Inc. Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 35,163 shares of NUVL stock, worth $3.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,163

Previous 28,252 24.46%

Holding current value

$3.48 Million

Previous $2.12 Million 25.74%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$62.76 - $81.61 $433,734 - $564,006	6,911 Added 24.46%	35,163 $2.67 Million
Q1 2024 Jul 01, 2024	BUY	$72.35 - $88.99 $77,197 - $94,952	1,067 Added 3.92%	28,252 $2.12 Million
Q1 2024 May 14, 2024	SELL	$72.35 - $88.99 $72,132 - $88,723	-997 Reduced 3.54%	27,185 $2.04 Million
Q4 2023 Feb 15, 2024	BUY	$42.42 - $80.28 $250,065 - $473,250	5,895 Added 26.45%	28,182 $2.07 Million
Q3 2023 Nov 14, 2023	SELL	$39.12 - $49.85 $7,080 - $9,022	-181 Reduced 0.81%	22,287 $1.02 Million
Q2 2023 Aug 14, 2023	BUY	$23.58 - $44.68 $226,721 - $429,598	9,615 Added 74.81%	22,468 $947,000
Q1 2023 May 15, 2023	BUY	$25.42 - $33.52 $164,009 - $216,271	6,452 Added 100.8%	12,853 $335,000
Q4 2022 Feb 14, 2023	BUY	$18.46 - $36.37 $90,583 - $178,467	4,907 Added 328.45%	6,401 $190,000
Q2 2022 Aug 22, 2022	SELL	$7.4 - $15.07 $2,020 - $4,114	-273 Reduced 15.45%	1,494 $20,000
Q1 2022 May 16, 2022	BUY	$11.65 - $19.57 $8,912 - $14,971	765 Added 76.35%	1,767 $25,000
Q3 2021 Nov 15, 2021	BUY	$18.25 - $38.35 $18,286 - $38,426	1,002 New	1,002 $22,000

Others Institutions Holding NUVL

# of Institutions

178

Shares Held

56.6M

Call Options Held

527K

Put Options Held

131K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $4.26B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Nuvalent, Inc. Transaction History